Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is a promising biotech company with a positive outlook due to its diverse pipeline of two potential blockbuster drugs, EVO756 and EVO301, targeting chronic inflammatory diseases. Despite the disappointment from EVO756's negative Phase IIb CSU trial, the company still has significant upside potential with upcoming readouts for AD and migraine. Additionally, Evommune's differentiated approach through MRGPRX2 inhibition has shown promise in CIndU and could potentially be applied to other indications in the future. With an estimated $200M opportunity in AD and $700M in migraine, Evommune is a strong investment opportunity in the biotech sector.

Bears say

Evommune is a relatively small biotechnology company with a narrow focus on chronic inflammatory diseases and a limited pipeline of potential therapies. Additionally, the company lacks diversity and social initiatives, which may affect their ability to attract and retain top talent. The upcoming clinical trial data for their lead candidate, EVO756, will be crucial in determining the potential success of the company. However, their reliance on early clinical class MRGPRX2 and potential safety concerns may limit their market appeal.

Evommune Inc (EVMN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 8 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.